Russell Investments Group Ltd. Acquires 1,177 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Russell Investments Group Ltd. Acquires 1,177 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Updated: 1 month, 10 hours, 54 minutes, 33 seconds ago

Russell Investments Group Ltd. increased its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Get Rating) by 6.7% in the second quarter, according to its most recent filing with the SEC. The fund owned 18,772 shares of the medical research company’s stock after acquiring an additional 1,177 shares during the period. Russell Investments Group Ltd.’s holdings in Charles River Laboratories International were worth $4,023,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of CRL. Allspring Global Investments Holdings LLC lifted its stake in shares of Charles River Laboratories International by 1,739.4% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 645,263 shares of the medical research company’s stock worth $138,065,000 after acquiring an additional 610,182 shares during the last quarter. Mackenzie Financial Corp increased its holdings in Charles River Laboratories International by 182.5% during the 1st quarter. Mackenzie Financial Corp now owns 856,214 shares of the medical research company’s stock worth $243,139,000 after purchasing an additional 553,121 shares during the period. Clearbridge Investments LLC increased its holdings in shares of Charles River Laboratories International by 28.2% in the 1st quarter. Clearbridge Investments LLC now owns 1,368,943 shares of the medical research company’s stock valued at $388,739,000 after acquiring an additional 301,159 shares during the period. First Republic Investment Management Inc. increased its holdings in shares of Charles River Laboratories International by 3,792.3% in the 1st quarter. First Republic Investment Management Inc. now owns 156,277 shares of the medical research company’s stock valued at $44,378,000 after acquiring an additional 152,262 shares during the period. Finally, BlackRock Inc. increased its holdings in shares of Charles River Laboratories International by 3.0% in the 1st quarter. BlackRock Inc. now owns 5,230,033 shares of the medical research company’s stock valued at $1,485,173,000 after acquiring an additional 150,007 shares during the period. 95.20% of the stock is owned by institutional investors.

Get Charles River Laboratories International alerts:

Insider Buying and Selling

In related news, EVP Joseph W. Laplume sold 200 shares of the company’s stock in a transaction dated Friday, August 5th. The stock was sold at an average price of $226.13, for a total value of $45,226.00. Following the completion of the transaction, the executive vice president now owns 20,766 shares of the company’s stock, valued at approximately $4,695,815.58. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.10% of the stock is currently owned by insiders.

Charles River Laboratories International Stock Performance

Shares of CRL stock opened at $221.18 on Thursday. The stock has a market cap of $11.25 billion, a PE ratio of 25.66, a price-to-earnings-growth ratio of 1.33 and a beta of 1.29. Charles River Laboratories International, Inc. has a 52-week low of $181.36 and a 52-week high of $449.34. The company has a quick ratio of 1.08, a current ratio of 1.33 and a debt-to-equity ratio of 1.13. The business has a 50-day simple moving average of $203.62 and a 200-day simple moving average of $224.19.

Charles River Laboratories International (NYSE:CRL – Get Rating) last released its quarterly earnings results on Wednesday, August 3rd. The medical research company reported $2.77 earnings per share for the quarter, topping analysts’ consensus estimates of $2.74 by $0.03. The company had revenue of $973.13 million during the quarter, compared to analysts’ expectations of $995.12 million. Charles River Laboratories International had a return on equity of 21.51% and a net margin of 12.02%. Charles River Laboratories International’s quarterly revenue was up 6.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.61 EPS. On average, equities analysts expect that Charles River Laboratories International, Inc. will post 10.76 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. Jefferies Financial Group upgraded Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $240.00 price target on the stock in a report on Thursday, September 29th. Citigroup dropped their target price on Charles River Laboratories International to $280.00 in a research note on Tuesday, August 9th. StockNews.com initiated coverage on Charles River Laboratories International in a research note on Wednesday, October 12th. They set a “hold” rating on the stock. Morgan Stanley downgraded Charles River Laboratories International from an “overweight” rating to an “equal weight” rating and dropped their target price for the stock from $350.00 to $250.00 in a research note on Thursday, August 4th. Finally, Deutsche Bank Aktiengesellschaft lowered their price target on Charles River Laboratories International from $290.00 to $270.00 in a research report on Monday, August 8th. Three equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $314.33.

About Charles River Laboratories International

(Get Rating)

Charles River Laboratories International, Inc, a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

Read More

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL – Get Rating).

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.